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Introduction and defi  nitions
Idiopathic pulmonary ﬁ  brosis (IPF) is a dreadful, chronic, 
and irreversibly progressive ﬁ  brosing disease leading to 
death in all patients aﬀ   ected, and IPF exacerbations 
constitute the most devastating complication during its 
course [1-6]. IPF exacerbations appear more frequently 
than previously thought and represent a common termi-
nal event [7,8]. IPF lacks eﬀ  ective treatment, and survival 
is approximately 3 years [2,6,9,10]. Best supportive care 
constitutes the only attainable therapeutic strategy and 
includes a more or less eﬀ   ective attempt to alleviate 
symptoms and prevent complications and a far more 
eﬃ     cacious interventional approach consisting of the 
withdrawal of corticosteroids and immunosuppressants 
(commonly administered by clinicians) that are in-
eﬀ  ective and harmful [2,9,11]. Transplantation is the only 
thera  peutic option [12].
IPF exacerbations represent acute and clinically 
signiﬁ  cant deteriorations of unidentiﬁ  able cause, trans-
form  ing the slow and more or less steady disease decline 
[13] to the unexpected appearance of acute lung injury/
acute respiratory distress syndrome (ALI/ARDS) ending 
in death [6,14]. Occasionally, IPF exacerbations may 
present in a previously apparently healthy or minimally 
symptomatic individual and might represent acute 
progression of an unsuspected or undiagnosed early IPF 
[3,15]. Deﬁ   nition criteria include IPF diagnosis, un-
explained worsening or development of dyspnea within 
30 days, new lung inﬁ  ltrates (mainly ground glass upon 
honeycomb), and exclusion of any identiﬁ  able  or 
treatable cause of lung injury [6]. Surgical lung biopsy per 
se constitutes a risk factor for their development [16] but, 
when performed for the investigation of the etiology of 
exacerbations or in autopsies, discloses a histological 
picture of diﬀ  use alveolar damage (DAD), which is the 
ARDS tissue counterpart, upon usual interstitial 
pneumonia (UIP), which is the IPF tissue equivalent 
[4,8,17-19].
In IPF, anachronic and reiterative epithelial injury and 
loss of the alveolar-capillary integrity constitute the 
initial event and ‘the point of no return’ that trigger aber-
rant repair pathways leading to inappropriate, progres-
sive, and heterogeneous lung scarring (UIP) [20-22]. 
DAD upon UIP might represent massive epithelial and 
endothelial injury of the lung areas yet preserved from 
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© 2010 BioMed Central Ltdscarring [9,23]. Putative initiators of IPF include viruses, 
cigarette smoke, gastroesophageal reﬂ   ux, and occupa-
tional exposure to wood and metals [24,25]. Aging, by 
reducing eﬃ     ciency in repairing damage, represents a 
cofactor [26]. Th  e development of DAD upon UIP may 
relate to a clinically occult infection [14,27], aspiration, or 
a distinct pathobiological manifestation of IPF [6]. 
‘Treatment’ with high-dose corticosteroids with or 
without an immunosuppressant proved ineﬀ  ective and 
represents the coup de grace for these patients [8]. IPF 
exacerbations require rapid decisions about when and 
whether to initiate mechanical support. However, the 
con  sideration of admission to an intensive care unit 
(ICU) is a particular clinical and ethical challenge 
because of poor outcome [28-32]. Transplantation in this 
setting presents insurmountable diﬃ   culties.
Epidemiology and risk factors
Th   e incidence of IPF exacerbations varies greatly between 
studies (from 8.5% to 60%) mainly because of diﬀ  erences 
in their design [3-6,8,14,16,19,28,29,31-35]: (a) case series 
and retrospective cohorts [4,17-19], (b) randomized con-
trolled trials of speciﬁ  c treatments for IPF [3], (c) autopsy 
reviews [8,16,33], and (d) retrospective reviews of ICU 
admissions [28,29,31,32]. Discrepancies in reported fre-
quen  cies should be attributed to the diﬃ   culty in strictly 
respecting the deﬁ   nition criteria especially concerning 
symptom duration (less than 4 weeks) and the deﬁ  nite 
exclusion of infection [3,6,36]. IPF exacerbations do not 
appear to be linked to disease duration, functional 
derange  ment, age, gender, or smoking history [4,29], 
although further studies are necessary to conﬁ  rm early 
development as well as lack of association with immuno-
suppression [37]. Exacerbation mortality approaches 
100%, questioning the need for ICU admission [2-6,8,  14, 
16, 19, 28, 29, 31-34].
Etiologic and pathogenetic considerations
Th  e deﬁ   nition of IPF exacerbations ‘after excluding 
identi ﬁ   able causes of lung injury’ implies that in 
‘idiopathic’ pulmonary ﬁ  brosis, ‘idiopathic’ exacerbations 
occur [3,4,6]. However, in clinical practice, when such a 
patient is referred to the emergency department (ED), 
the attending clinician has to face one of three clinical 
scenarios [38] (Figure 1). Th  e  ﬁ  rst scenario is the case in 
which the physical evolution of IPF comes to the ﬁ  nal 
end in which spontaneous breathing becomes unsup  por-
table [39] (Figures 1a and 2). In this scenario, the 
exclusion of ‘identiﬁ  able-treatable causes of lung deteri-
or  ation’ is demanding, but the only option attainable is 
palliation. Th   e second scenario refers to ‘true’ IPF exacer-
bation that brings the patient to the ED (Figures 1b and 
3). In this case, after admission to the hospital ward, the 
patient usually becomes unable to maintain spontaneous 
breathing within hours or very few days, often not 
enough time for the extensive work-up required to 
identify treatable factors of deterioration, and needs 
ventilatory support and ICU transfer [5,7,8]. Th  e third 
scenario refers to the admission to the hospital ward of 
an IPF-deteriorated patient because of reversible causes 
either aﬀ   ecting the lung or not; in this case, early 
identiﬁ   cation of the precipitating factor(s) and their 
prompt treatment are imperative (Figures 1c and 4). 
Nevertheless, borders between the above scenarios are 
unclear in routine clinical practice since exacerbations 
occur as a spectrum rather than a clearly deﬁ  nable event.
However, even after the exclusion of any identiﬁ  able 
and treatable factor(s) inducing IPF exacerbations, the 
most important etiologic hypothesis remains that of a 
clinically occult infection that precipitates an already 
UIP-scarred lung into DAD [6]. For several reasons, 
viruses are the best etiologic candidates: (a) Epstein-Barr, 
cytomegalovirus, hepatitis C, herpes simplex, parvovirus 
B19, torque teno, and especially herpes viruses 7 and 8 
have been implicated in IPF pathogenesis [40-42]; (b) ﬂ  u-
like illness heralds the onset of exacerbations, and IPF 
mortality seems to peak in winter time and coincides 
with the peak of viral respira  tory infections [43]; (c) in 
the mice pulmonary ﬁ   brosis experimental model, 
gamma  herpesvirus induces exacer  ba  tions [44] as well as 
other viruses in vivo [45]; and (d) latent lung viral 
infections may reactivate under immuno  suppression 
commonly used by clinicians [41]. Th  erefore, in IPF, 
viruses may act as both initiators and exacerbators 
because of their formidable ability to induce ARDS [46]. 
Besides viruses, microbials in traction bronchiectases/
bronchiolectases are equally strong candidates. Bron-
chiec  tases are among the most common of the whole 
spectrum of lesions that characterize the architectural 
distortion in IPF. Interleukin-8, neutrophils, and alpha-
defensins are increased or activated in stable or exacer-
bated patients with IPF [47,48] and possibly play a role in 
triggering ARDS. In addition, immunosuppressive 
treatment certainly increases suscep ti bility  to  microbials.
Accordingly, further considerations have to be made. 
ALI/ARDS, acute interstitial pneumonia (AIP), and IPF 
exacerbations have common clinical, physiological, 
imaging, and histopathology features, and it is incon  ceiv-
able that they do not also have common etiopathogenetic 
mechanisms (Figure 5). ALI/ARDS develops by diﬀ  erent 
insults to the lung, and the mainstay of its treatment is 
provision of excellent supportive care and etiologic 
manage  ment of the underlying cause [46]. AIP is pre-
cisely an ARDS of ‘unknown cause’, and no speciﬁ  c 
clinical clues to diﬀ  erentiate between ‘known and un-
known cause’ ARDS exist [49]. Criteria for the diagnosis 
of AIP are the same as in IPF exacerbations with the 
exception of the ‘incubation’ time (2 months instead of 
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Page 2 of 104 weeks) and the prerequisite of normal chest roent  geno-
gram. AIP, incomprehensibly, is included among the 
idiopathic interstitial pneumonias (IIPs) and probably 
should be added to the list of unknown cause ALI/ARDS, 
although some believe that AIP may represent a fulmi-
nant presentation of IIP secondary to imprecise auto-
immune factors [1,2]. Although there are no controlled 
trials of speciﬁ  c treatment, intensive immunosuppression 
has been the mainstay of treatment (usually under the 
coverage of several broad-spectrum antimicrobials, 
although this is not always stated) because of the 
inclusion of AIP among the IIPs [50]. However, AIP 
mortality approaches that of IPF exacerbations, and the 
provision of excellent suppor  tive care and further search 
of underlying causative factors and adequate treatment 
seem more logical. In stable IPF (in contrast to other 
pneumonias), lung damage is not resolved by restitutio 
ad integrum. IPF exacerbations characterized by DAD 
upon UIP may represent the acute response of scarred 
and irreparably damaged lung. Epithelial cell apoptosis 
involves and is considered to be among the main patho-
genetic mechanisms in the development of any DAD 
[51,52]. Th   erefore, it seems incoherent that DAD, which 
is the common denominator of all ALI/ARDS, AIP, and 
IPF exacerbations and which develops upon diﬀ  erent 
histology substrates (UIP in IPF exacerbations, normal 
lungs in AIP, and normal or diseased lungs in ARDS), 
presents at diﬀ   erent time intervals (7 days for ARDS 
[46,53], 4 weeks for IPF exacerbations [7], and 2 months 
for AIP [1]) and requires diﬀ  erent  pharmacologic 
approaches, which proved certainly fatal in AIP and in 
IPF ‘true’ exacerbations.
Clinical and laboratory assessment
Early, accurate, and secure diagnosis is critical in IPF-
exacer  bated patients with reversible precipitating 
Figure 1. Clinical scenarios for the idiopathic pulmonary fi  brosis (IPF) patient presenting in the emergency department with subacute/
acute dyspnea. (a) Progression to the fi  nal end of the disease. (b) ‘True’ IPF exacerbation. (c) IPF exacerbation due to treatable causes. Acute 
exacerbation (AE) criteria are presented in [7]. For details about laboratory tests and blood/sputum/bronchoalveolar lavage (BAL) tests, see the 
‘Clinical and laboratory assessment’ section. Cardiac echo, cardiac echocardiography; CTPA, computed tomography pulmonary angiography; HRCT, 
high-resolution computed tomography; ICU, intensive care unit; PE, pulmonary embolism; PH, pulmonary hypertension; PNX, pneumothorax; 
proBNP, pro-brain natriuretic peptide.
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should focus on smoking habits, toxic exposures, pre-
scribed medications, immunosuppression, and signs and 
symptoms of potentially undiagnosed autoimmune rheu-
matic disease [2,54,55]. Physical examination frequently 
reveals tachypnea, cyanosis, digital clubbing, bilateral 
inspiratory crackles, and lower extremity edema. In the 
most severe cases, the patient may be obtund or coma-
tose because of severe hypoxemic and potentially hyper-
capnic respiratory failure. Th  e presence of arrhyth  mias, 
chest pain, hemoptysis, or hemodynamic instability 
should guide the physician to an overlapping or 
alternative diagnosis such as acute coronary syndrome or 
pulmonary embolism.
Chest roentgenograms, including past imaging data, 
may help to orientate the clinician toward the identi-
ﬁ  cation of the causative agents of the exacerbation. Com-
puted tomo  graphy pulmonary angiography is mandatory 
to exclude pulmonary embolism, and high-resolution 
computed tomography (HRCT) may document extension 
Figure 2. Idiopathic pulmonary fi  brosis (IPF) progressing to the fi  nal end. Roentgenograms of a 57-year-old female (a) 6 years before diagnosis 
(normal) and (b) at the time of diagnosis of IPF. The latter reveals a bilateral reticular pattern. (c) High-resolution computed tomography shows 
mild reticulation. (d) Roentgenogram of the patient 24 months after diagnosis demonstrates worsening of the reticular pattern superimposed on 
a ground-glass pattern. The patient was admitted with severe breathlessness and productive cough. Her symptoms were severely aggravated in 
the last 9 months and she was hospitalized many times. She had received corticosteroids and mycophenolate mofetil, which were discontinued 
months prior to this roentgenogram because of lower respiratory tract infections. At the time of the roentgenogram, she was receiving only proton 
pump inhibitors. She deteriorated further despite best supportive care and died while on palliation treatment. Our putative diagnosis was IPF 
progressing to the fi  nal end.
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Echo  cardio  graphy may also be useful. When early undiag-
nosed IPF presents with fulminant respiratory insuﬃ   -
ciency and ARDS [3,29], honeycombing with bibasilar and 
subpleural distribution on HRCT [1] can establish the 
diagnosis of IPF exacerbation and diﬀ  eren  tiate deﬁ  nitely 
from AIP [49]. In IPF exacerbations, HRCT reveals new 
bilateral ground-glass abnormalities or consolidations (or 
both) upon UIP pattern [6]. A ground-glass pattern, 
especially if extensive, is not a feature of stable IPF, and 
its rapid development away from areas of ﬁ  brosis heralds 
DAD. Akira and colleagues [18,56] have proposed a 
classiﬁ  cation of acute exacer  bations of IPF on the basis of 
three ground-glass and consolidation computed tomo-
graphy patterns that appear to have prognostic implica-
tions: (a) peripheral, (b) multifocal, and (c) diﬀ  use, 
though others did not conﬁ  rm a similar assumption [57].
Since no laboratory test is speciﬁ  c to IPF exacerbations, 
most tests are performed to exclude treatable causes of 
deterioration and to document the severity of the exacer-
bations. Th   e standard laboratory work-up should include 
all necessary tests for the investigation of a critically ill 
patient with impeding ALI/ARDS of unknown etiology. 
ALI and ARDS criteria (arterial partial pressure of 
oxygen/fraction of inspired oxygen [PaO2/FiO2] of less 
than 300 and less than 200, respectively) should prepare 
the clinician for the possibility of mechanical support. 
Accurate diagnosis in IPF exacerbations requires broncho  -
alveolar lavage (BAL) to exclude infection or alternative 
diagnoses; BAL is best performed before mechanical 
support or immediately afterwards [2]. Perform  ing lung 
biopsy could be justiﬁ  able when facing a disease with 
grave prognosis but bears an increased risk for post-
surgical complications and should be individual  ized to 
each patient [2].
Current management
IPF exacerbations lack an eﬀ  ective treatment. Intensive 
immunosuppression proved harmful and fatal [2]. Patients 
presenting with IPF exacerbations must be managed in 
centers specializing in interstitial lung diseases (ILDs) with 
the availability of various specialties and departments such 
as a respiratory ward with a respiratory ICU/high-
dependency unit (RICU/HDU), an ICU, and possibly a 
cardiothoracic transplantation center on a 24-hour basis. 
Lung transplantation constitutes a treat  ment option for 
IPF ‘true’ exacerbations [2,38] but faces insurmountable 
diﬃ   culties, even in specialized centers.
Management depends on the clinical scenario 
(Figure  1). In case of progression to the ﬁ  nal  end 
(Figure  1a), palliation is more appropriate [2]. Non-
invasive ventilation (NIV), by decreasing breathing work, 
is considered a major palliative option that, together with 
best supportive care, may help to reduce patient 
discomfort and permits management in an RICU [58,59]. 
Patients with ‘true’ IPF exacerbations (Figure 1b), in 
which the diagnostic approach fails to identify a possible 
infective etiology, must continue to receive empirical 
antimicrobial therapy that takes into consideration 
factors such as immunosuppression, previous coloniza-
tion, BAL timing, onset of mechanical support, and 
results of obtained cultures [2]. ‘Speciﬁ  c’ therapies for 
‘true’ IPF exacerbations until now have consisted of high-
dose intravenous corticosteroids plus an immuno-
suppressant [2]. However, Cochrane reviews for the 
eﬃ     cacy of these therapies concluded that there is no 
evidence for any beneﬁ   t of both cortico  steroids and 
immunosuppressants in IPF [60,61]. Besides, both 
progression of ﬁ   brosis on native lung in single-lung 
transplant patients and IPF ‘true’ exacerbations have 
been described in the heavily immunodepressed 
Figure 3. Idiopathic pulmonary fi  brosis (IPF) ‘idiopathic’ exacerbation. (a-c) High-resolution computed tomography in an IPF patient at three 
diff  erent parenchymal levels shows diff  use areas of ground-glass attenuation, bronchiolectasis, and honeycombing. The patient was a 71-year-old 
male physician recently diagnosed with IPF. He was self-administering high-dose oral corticosteroids for months and presented severe deterioration 
of dyspnea and cough and developed severe acute respiratory failure. Despite empirical treatment with broad-spectrum antimicrobials, he 
deteriorated and was intubated. He died in the intensive care unit 4 weeks later. Extensive work-up disclosed no causative factors.
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very few survivors from the IPF exacerbations and also 
constitutes the bridge to transplantation [62]. To 
promptly recognize and treat reversible precipitating 
factors implicated in IPF exacerbations (Figure 1c), 
recovery in the RICU/HDU or (in case of multiorgan 
failure) in the ICU is mandatory [63].
Toward the intensive care unit
An IPF patient is referred to the ICU for severe acute 
respiratory failure as a consequence of the clinical 
scenarios (mentioned above) that may lead to ventilatory 
support (Figure 1). Progression to the ﬁ  nal end reaches a 
point at which spontaneous ventilation in no longer 
possible (Figure 1a). ICU admission of these patients, 
because of the poor outcome, should be avoided [2] 
(Figure 2). In ‘true’ IPF exacerbations (Figure 1b), 
ventilatory support and ICU transfer buy time and could 
have some inﬂ  uence on ﬁ  nal outcome in speciﬁ  c patients. 
Unfortunately, in the vast majority, this does not happen, 
and the mortality of this patient population is high, 
higher even than that predicted by the usual clinical score 
Figure 4. Exacerbation of idiopathic pulmonary fi  brosis (IPF) due to treatable causes. (a) High-resolution computed tomography (HRCT) shows 
minimal evidence of apical interstitial lung disease. (b) HRCT shows, at the lung bases, ground-glass opacities upon extensive peripheral thickening 
of intralobular septa. The patient was a 65-year-old male with IPF and initiated treatment with high doses of corticosteroids. (c) Four months later, 
HRCT denotes diff  use ground-glass with irregular reticulation. Note the extensive lipomatosis of the mediastinum due to chronic steroid use. Owing 
to deterioration of dyspnea, he was admitted to another hospital, where bronchoalveolar lavage (BAL) was performed and the immunosuppressive 
treatment was intensifi  ed. A few weeks later, he was admitted to our department with respiratory failure, severe corticosteroid-related myopathy, 
diabetes mellitus, severe dyspnea, and purulent sputum. Clinical examination disclosed herpes simplex virus keratitis in the left eye, and BAL cultures 
grew positive for Pseudomonas aeruginosa. Corticosteroids were tapered, and antimicrobial and antiviral treatment was initiated. Both eye and lower 
respiratory tract infections subsided, and the patient was discharged home a few weeks later. (d) Eighteen months after the exacerbation, the ground-
glass opacities completely resolved as did the lipomatosis of the mediastinum. The patient is still alive and at home.
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because of reversible causes either aﬀ  ecting the lung or 
not (Figures 1c and 4) bears better prognosis, but special 
attention should be paid to avoid further complications. 
Th  e complexity of the above scenarios underscores the 
importance of good communication between referring 
and ICU physicians.
So far, the studies of IPF patients in the ICU have had 
many limitations (Table 1) [4,28,29,31,32,34,59,64]. Th  ese 
studies are usually retrospective and single-centered and 
include limited numbers of patients. In addition, most of 
these studies include all IPF patients admitted to the ICU 
for respiratory failure regardless of etiology, the propor-
tion of patients with conﬁ  rmed diagnosis is variable, the 
ventilator parameters are usually not reported, and the 
pharmacologic therapy demonstrates a signiﬁ  cant 
diversity. Th   e only common parameter is the conclusion: 
the prognosis of ventilated IPF patients is disappointing 
[2]. Given these results, what may be the goals of ICU 
support for a patient with an IPF exacerbation? Although 
deﬁ  nite conclusions cannot be drawn, there is a general 
feeling that mechanical ventilation and intensive support 
do not have a signiﬁ  cant eﬀ  ect on outcome [2]. Could 
this be due to the disease itself, ventilator-induced lung 
injury, complications of intensive support (sepsis, critical 
care myoneuropathy, or ventilator-associated pneu-
monia), or a combination of the above? Only assumptions 
can be made, and patients (at an earlier stage) and 
relatives as well as physicians outside of the ICU before 
or at admission should become aware of the poor 
prognosis. Th  is does not mean that IPF patients with 
acute respiratory failure should be denied admis  sion; in 
many hospitals, the ICU is the right place to perform in a 
safe and timely fashion the necessary extended investi-
gation to exclude reversible causes of deterioration in 
these patients.
Ventilating a patient with an IPF exacerbation is a 
diﬃ     cult and demanding task, and no ‘cookbook’ 
prescriptions can make the work easier for the intensivist. 
Th   e evidence for the best ventilator strategy applying to 
an IPF exacerbation is extremely scarce, and the eﬀ  ect of 
ventilatory management on outcome has not been 
system  atically assessed; therefore, every suggestion is 
based on theoretical principles and pathologic data that 
are characterized mainly by extended DAD [7]. Recently, 
Bates and colleagues [65] introduced the concept of 
percolation, according to which the progression of 
parenchymal lung disease can suddenly reach a threshold 
that dramatically alters the mechanical properties of the 
lung. IPF exacerbations that require ventilator support 
could be an example of crossing this percolation 
threshold. Under these circumstances, mechanical venti-
la  tion could represent a second hit for the lung paren-
chyma, further deteriorating the mechanical properties 
of lung parenchyma and introducing a vicious cycle that 
ends in death. Mechanical ventilation with conventional 
volumes (8 mL/kg) in patients without lung injury can 
induce severe surfactant impairment, and sustained 
plasma cytokine production has been demonstrated in 
patients without ALI ventilated with conventional tidal 
Figure 5. Diff  erent clinical settings characterized by diff  use alveolar damage (DAD) pathology. This non-proportional fi  gure denotes the 
incoherence of the clinical signifi  cance of acute respiratory distress syndrome (ARDS), acute interstitial pneumonia (AIP), and idiopathic pulmonary 
fi  brosis (IPF) exacerbations in which DAD, despite being the common denominator, develops upon diff  erent histology substrates (UIP in IPF 
exacerbations, normal lungs in AIP, and normal or diseased lungs in ARDS) and, according to current defi  nitions, presents at diff  erent time intervals: 
7 days for ARDS, 4 weeks for IPF exacerbations, and 2 months for AIP. This incoherence led also to a diff  erent pharmacologic approach, which 
proved to be unsuccessful at least in AIP and in IPF  true  exacerbations. ALI, acute lung injury.
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low tidal volumes (6 mL/kg) [66,67]. So it should not be 
surprising, although it may be very diﬃ   cult to prove, that 
the employment of traditional tidal volumes in patients 
with IPF exacerbations would be detrimental given that 
their lungs are characterized by extended parenchymal 
alterations, severe inhomogeneity, and decreased compli-
ance even prior to initiation of mechanical ventilation. 
Especially the inhomogeneity of the lung parenchyma 
could cause severe overinﬂ   ation of the ‘healthy’ lung 
units with higher compliance and jeopardize the ‘healthy’ 
parenchyma left. A ventilation strategy employing low 
tidal volumes (4 to 6 mL/kg ideal body weight), such as 
that used for patients with ARDS, seems prudent and is 
advised by many experts [68]. Positive end-expiratory 
pressure (PEEP) should be used moderately because of 
the aforementioned risk of overinﬂ  ation of intact lung 
units. Fernández-Pérez and colleagues [64] demonstrated 
that high PEEP was independently associated with 
increased mortality in chronic ILD [64]. In the same 
context, there is no place for recruitment or prone 
position [69]. Given that intubated patients with IPF 
exacerbations require high-minute volume because of 
increased dead space, the respiratory frequency should 
be increased to the maximum acceptable rate and the 
target of a normal PaCO2 (arterial partial pressure of 
carbon dioxide) should be abandoned. Th   is high respira-
tory rate might require the use of heavy sedation and 
quite often paralysis, and care should be given to avoid 
auto-PEEP [70]. Th  e eﬀ   ect of prolonged sedation and 
paralysis on the neuromuscular function of these 
patients, who have often been administered steroids for a 
long time, is an unavoidable cost. Th  e earliest possible 
interruption of sedation will facilitate weaning provided 
that gas exchange and lung mechanics have improved.
NIV has some theoretical advantages in IPF patients 
and has been used extensively in cases of acute 
respiratory failure to avoid intubation. Unfortunately, the 
studies about its use have the same methodological 
problems as those for the invasive ventilation studies 
mentioned previously, and no ﬁ  rm conclusions can be 
drawn. Th  ere are two things that make NIV more 
‘attractive’ in this setting: the almost absolute mortality 
that invasive mechanical ventilation carries and the 
avoidance of intubation and ventilation risks (aspiration, 
ventilator-associated pneumonia, and ventilator-
associated injury). Th   e problem is that in most cases the 
excessive work of breathing associated with IPF exacer-
bation cannot be managed eﬀ  ectively by NIV. Extracor-
poreal membrane oxygenation could represent a valuable 
adjunct to conventional treatment for selected cases of 
IPF. Limited availability, high cost, complicated tech-
nology, and increased rates of complications have been 
the most important factors limiting its use so far [71-73]. 
In the setting of IPF therapeutics, it has been used mainly 
as a bridge to transplantation [74]. Transplantation 
represents the ﬁ  nal line of defense for the IPF patient and 
is the only therapy with a proven survival beneﬁ  t. Early 
referral (even at the time of diagnosis) to a lung transplant 
center is mandatory [75] because of the prolonged 
waiting-list time, which sometimes exceeds the patient’s 
life expectancy.
Conclusions
IPF exacerbations constitute the most devastating 
compli  cation of IPF. Diﬀ  erent and hard-to-diﬀ  erentiate 
Table 1. Summary of published studies for idiopathic pulmonary fi  brosis patients in the intensive care unit. 
                
                
 Time    Ventilated  Biopsy  IPF    Ventilator    ICU  Hospital
Study frame  Patients  patients  proven  exacerbations  Therapya  settings  NIV  mortality  mortality
Stern et al. [29]  1991-1999  23  23  15/23 (65%)  16  91%  TV 8-13 mL/kg  NR  22/23 (96%)  22/23 (96%)
Blivet et al. [28]  1989-1998  15  15  7/15 (47%)  6  100%  NR  5  11/15 (73%)  13/15 (87%)
Saydain et al. [31]  1995-2000  38  19  18/38 (47%)  15/38  61%  NR  7  13/19 (68%)  23/38 (61%)b
Al-Hameed and   1988-2000  25  25  8/25 (32%)  25  100%  PEEP 7 cm H2O  3  21/25 (84%)  24/25 (96%)
Sharma [32]
Kim et al. [4]  1990-2003  10  9  7/9 (78%)  9  100%  NR  NR  (7/9) 78%  (7/9) 78%
Rangappa   1996-2006  24  19  33%  8  71%  NR   (16/24) 67%  (22/24) 92%
and Moran [34]
Fernández-Pérez   2002-2006  30 30  17/30 (57%)  NR  30%  TV 7 mL/kg  NR  NR  (11/16) 69%
et al. [64]    (14 S, 16 M)
Mollica et al. [59]  2000-2007  34  34   16/34 (47%)  22  100%  TV 7.5 mL/kg  19  100% for  (29/34) 85%c
      (15 INV, 19 NIV)          INV, 73% for NIV
All studies were single-center retrospective. aTherapy consisted of corticosteroids plus immunosuppressants. bNinety-two percent of the survivors died at a median 
of 2 months after hospital discharge. cFour out of fi  ve survivors died shortly after hospital discharge. ICU, intensive care unit; INV, invasive ventilation; IPF, idiopathic 
pulmonary fi  brosis; M, medical; NIV, non-invasive ventilation; NR, not reported; PEEP, positive end-expiratory pressure; S, surgical; TV, tidal volume.
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deﬁ  nition: subacute/acute deterioration of dyspnea and 
bilateral chest inﬁ   ltrates, corresponding in ‘true’ IPF 
exacerbations, to a tissue pattern of DAD upon UIP. Also, 
ALI/ARDS and AIP present DAD. Intensive immuno-
suppression proved ineﬀ  ective and represents the coup 
de grace for these patients. Provision of excel  lent 
supportive care and the search for and treatment of the 
‘underlying cause’ remain the only options. Th  e  unravel-
ling of Ariadne’s thread continues.
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